secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cartesian Therapeutics, Inc. (RNAC)
CIK:        0001453687
Form:       8-K
Filed at:   2023-04-04T23:59:59+00:00
Accession:  0001453687-23-000043
Event type: debt
Sentiment:  neutral
Materiality: 0.55
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Selecta Biosciences amends loan agreement, eases SVB collateral account requirement
--------------------------------------------------------------------------------

- Fourth Amendment to Loan and Security Agreement dated March 31, 2023 with Oxford Finance and SVB (First-Citizens).
- Relaxes Section 6.6: must hold lesser of 100% consolidated cash or 150% outstanding obligations in SVB collateral accounts.
- Borrower released all claims against lenders arising from loan documents.
- Updates references to SVB to reflect its acquisition by First-Citizens Bank & Trust Company.
- No Event of Default exists after amendment; representations and warranties reaffirmed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1453687/000145368723000043/0001453687-23-000043-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1453687/000145368723000043/selb-20230331.htm
  HTML page:      https://secwatch.observer/filing/0001453687-23-000043

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer